Rpo LLC Takes Position in Alector, Inc. (NASDAQ:ALEC)

Rpo LLC purchased a new position in Alector, Inc. (NASDAQ:ALEC) during the fourth quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor purchased 26,395 shares of the company’s stock, valued at approximately $50,000.

Several other hedge funds have also recently bought and sold shares of the company. Intech Investment Management LLC purchased a new stake in Alector during the third quarter worth $90,000. Charles Schwab Investment Management Inc. increased its holdings in Alector by 14.1% during the 3rd quarter. Charles Schwab Investment Management Inc. now owns 760,606 shares of the company’s stock valued at $3,544,000 after acquiring an additional 94,145 shares in the last quarter. FMR LLC increased its holdings in Alector by 1.0% during the 3rd quarter. FMR LLC now owns 14,595,014 shares of the company’s stock valued at $68,013,000 after acquiring an additional 137,794 shares in the last quarter. Erste Asset Management GmbH acquired a new position in Alector during the third quarter worth about $93,000. Finally, Point72 Asia Singapore Pte. Ltd. purchased a new stake in shares of Alector in the third quarter valued at about $40,000. 85.83% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

A number of equities research analysts recently issued reports on the company. Mizuho lowered Alector from an “outperform” rating to a “neutral” rating and reduced their target price for the company from $9.00 to $2.50 in a research note on Tuesday, December 17th. Bank of America downgraded Alector from a “neutral” rating to an “underperform” rating and reduced their price objective for the company from $9.00 to $1.00 in a research report on Wednesday, December 4th. Stifel Nicolaus cut Alector from a “buy” rating to a “hold” rating and set a $4.00 price objective for the company. in a research report on Monday, December 16th. Morgan Stanley restated an “underweight” rating and issued a $1.50 target price (down from $3.00) on shares of Alector in a report on Friday, March 7th. Finally, HC Wainwright reiterated a “buy” rating and set a $7.00 price target on shares of Alector in a report on Thursday, February 27th. Two research analysts have rated the stock with a sell rating, two have issued a hold rating and three have issued a buy rating to the company’s stock. According to data from MarketBeat.com, Alector presently has an average rating of “Hold” and an average price target of $3.50.

Alector Trading Up 1.7 %

Shares of NASDAQ:ALEC opened at $1.18 on Thursday. Alector, Inc. has a 12-month low of $1.11 and a 12-month high of $6.78. The stock’s 50-day moving average price is $1.56 and its two-hundred day moving average price is $2.88. The firm has a market cap of $116.92 million, a price-to-earnings ratio of -0.69 and a beta of 0.65.

Alector (NASDAQ:ALEC) last released its earnings results on Wednesday, February 26th. The company reported ($0.02) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.61) by $0.59. Alector had a negative net margin of 257.54% and a negative return on equity of 108.77%. The business had revenue of $54.24 million for the quarter, compared to analysts’ expectations of $20.41 million. As a group, research analysts forecast that Alector, Inc. will post -1.88 earnings per share for the current fiscal year.

About Alector

Alector, Inc, a clinical stage biopharmaceutical company, develops therapies for the treatment of neurodegeneration diseases. Its products include AL001, an immune activity in the brain with genetic links to multiple neurodegenerative disorders, which is in Phase III clinical trial for the treatment of frontotemporal dementia, Alzheimer's, Parkinson's, and amyotrophic lateral sclerosis diseases; and AL101 that is in Phase I clinical trial for the treatment of neurodegenerative diseases, including Alzheimer's and Parkinson's diseases.